Self‐reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side‐study

Schilder, Christina M.; Seynaeve, Caroline; Linn, Sabine C.; Boogerd, Willem; Beex, L.V.A.M.; Gundy, Chad M.; Nortier, J.W.R.; Velde, Cornelis J.H. van de; Dam, F.S.A.M. van; Schagen, Sanne B.

doi:10.1002/pon.1928

Cited by 52 publications

(49 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Schilder et al . also found different patterns for SCF measured with an interview and with the CFQ‐25 items in BC patients, but a limitation of this study is that the used interview was non‐validated and that the response scale of this interview was dichotomous (e.g., Do you have complaints with regard to memory? (yes/no)).…”

Section: Discussionmentioning

confidence: 87%

Chemotherapy and cognitive complaints in women with breast cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 87%

Chemotherapy and cognitive complaints in women with breast cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The TEAM trial published self-reported neuropsychological outcomes and showed that neither tamoxifen nor exemestane increased the reports of cognitive failures compared with healthy controls (Schilder et al , 2011). However, little data are available on the post-treatment impact on QoL in these studies (Fallowfield, 2007).…”

Section: Discussionmentioning

confidence: 99%

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

et al. 2012

View full text Add to dashboard Cite

Background:The Intergroup Exemestane Study (IES) (ISRCTN11883920) demonstrated improved survival for postmenopausal women with ER-positive/unknown primary breast cancer who switched to exemestane after 2–3 years tamoxifen, compared with those continuing on tamoxifen to complete 5 years therapy. This was achieved without detriment to on-treatment quality-of-life (QoL). We report on- and post-treatment QoL impact in IES.Methods:A total of 582 patients from 8 countries participated in the QoL substudy. Functional Assessment of Cancer Therapy–Breast (FACT-B) and endocrine symptom subscale (ES) were completed at baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 months. The primary endpoint was FACT-B Trial Outcome Index (TOI); secondary endpoints included severity of individual endocrine symptoms.Results:Both the groups showed gradual improvement in overall QoL and lessening of total endocrine symptoms post treatment compared with baseline (P<0.002). There was no evidence of any between-group differences in TOI. Vasomotor complaints remained high on treatment. Vaginal discharge was more frequent (P<0.01) with tamoxifen up to 24 months from baseline. In both the groups, post-treatment libido did not recover to baseline levels.Conclusion:Clinical benefits of switching to exemestane are accompanied by good overall QoL. Although some symptoms persist, the majority of endocrine symptoms improve after treatment completion.

show abstract

“…While many studies have investigated the impact of chemotherapy, other studies have evaluated the impact of radiation therapy and hormonal therapies on cognitive function and found deficits in similar domains as with chemotherapy treatments (Castellon et al, 2004; Kohli et al, 2007; Schilder et al, 2009; Schilder et al, 2010; Schilder et al, 2012). Studies with comparison groups of patients treated with chemotherapy to those with hormonal therapies both show declines compared to healthy controls suggesting that hormone therapies can also lead to CRCI (Ahles, et al, 2010), and the combined treatment of tamoxifen and chemotherapy leads to greater difficulties than chemotherapy alone (Castellon, et al, 2004) (Palmer et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Prevalence, mechanisms, and management of cancer-related cognitive impairment

Janelsins

Kesler

Ahles

et al. 2014

International Review of Psychiatry

584

485

View full text Add to dashboard Cite

This review summarizes the current literature on cancer-related cognitive impairment (CRCI) with a focus on prevalence, mechanisms, and possible interventions for CRCI in those who receive adjuvant chemotherapy for non-central nervous system tumors and is primarily focused on breast cancer. CRCI is characterized as deficits in areas of cognition including memory, attention, concentration, and executive function. Development of CRCI can impair quality of life and impact treatment decisions. CRCI is highly prevalent; these problems can be detected in up to 30% of patients prior to chemotherapy; up to 75% of patients report some form of CRCI during treatment, and CRCI is still present in up to 35% of patients many years following completion of treatment. While the trajectory of CRCI is becoming better understood, the mechanisms underlying the development of CRCI are still obscure; however, host characteristics, immune dysfunction, neural toxicity, and genetics may play key roles in the development and trajectory of CRCI. Intervention research is limited, though strategies to maintain function are being studied with promising preliminary findings. This review highlights key research being conducted in these areas, both in patient populations and in animals, which will ultimately result in better understanding and effective treatments for CRCI.

show abstract

Self‐reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side‐study

Cited by 52 publications

References 49 publications

Chemotherapy and cognitive complaints in women with breast cancer

Chemotherapy and cognitive complaints in women with breast cancer

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

Prevalence, mechanisms, and management of cancer-related cognitive impairment

Contact Info

Product

Resources

About